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1 As they described, one of the unique characteristics of RCC might be a biological potential for recurrence or metastasis over 5 years after primary surgical treatment with curative intent. 2, 3 In the present study, 8.3% of the patients who underwent primary radical surgery and remained free of recurrence after 5 years had late recurrence of disease, which was consistent with the results in previous reports.
In terms of risk factors of late recurrence, a risk model (PRELANE score), including factors of lymphovascular invasion, Furman grade and tumor stage, had been recently developed and validated on the basis of a large multicenter database of the Western population.
3 The present study showed that vascular invasion (including microscopic and gross invasion) at the primary site was the only predictor of late recurrence, and the authors reported that larger primary tumor size and more aggressive tumor pathology might be risk factors of early rather than late recurrence.
1 In contrast, a previous study in the Japanese population reported that lymph node metastasis was the only factor to predict late recurrence. 4 Further large Japanese cohort studies will be expected to determine risk factors of late recurrence in Japanese RCC patients and to compare the findings with those in Western patients.
From the results regarding risk factors of late recurrence in the present study, the hypothesis that a lower malignant potential of cancer cells results in late recurrence might arise. As expected, Kaplan-Meier curves showed better overall and disease-specific survivals in patients with late than in those with early recurrence, and this finding was consistent with that of a previous study.
5 However, four (9.8%) patients with late recurrence had rapid disease progression and died within 1 year after recurrence. Alterations in the character of cancer before the recurrence clinically emerged were suggested, and the pathological and molecular mechanisms of these alterations should be elucidated in further examinations as the next challenging issue. LR is usually defined as recurrence more than 5 years after radical surgery. To characterize the clinical outcomes of all patients treated with radical surgery, it is reasonable to compare patients with LR to not only patients with early recurrence (ER; within 5 years after radical surgery), but also those without recurrence. A large study by Kroger et al. including 1210 patients reported that compared with patients with ER, patients with LR were younger, and showed fewer sarcomatoid features, more clear cell histology and lower Fuhrman grade.
3 The latest study on Japanese patients by Fujii et al. showed the following parameters to be independent predictive factors of ER: positive symptoms at diagnosis, ≥pT2, positive lymphovascular invasion and histological grade 3; 4 these results were similar to those of Kobayashi et al.
2 However, both Kroger et al. 3 and Fujii et al. 4 did not include patients without recurrence after 5 years of radical surgery. It might be difficult to compare patients with LR to those without recurrence, because the latter have the potential to relapse any time. Kobayashi et al. reported that vascular invasion alone was the predictor of LR in multivariate analysis of patients who remained free of recurrence at 5 years after radical surgery.
2 This result might be clinically significant with regard to the follow-up schedule of such patients. Kaplan-Meier curves of overall survival and disease-specific survival in patients with LR further decreased linearly by at least 5 years after recurrence. Furthermore, non-recurrence might contribute to the extension of survival. To appropriately treat recurrence, it should be detected as early as possible, and clinicians can shorten the follow-up interval of patients with vascular invasion.
Regardless of the study backgrounds, a common result of comparison between ER and LR was that patients with LR had a much better survival after recurrence. Bozkurt et al. reported that patients with LR had a better response to sunitinib than did those with ER.
5 Although slow growth might be a characteristic of LR, it is still unclear whether there are differences in responses to treatments such as molecular targeted therapies, cytokine therapies, and metastasectomy between ER and LR. Further larger studies are warranted to clarify the difference of response to treatments between ER and LR, and the best follow-up schedule to appropriately identify recurrence in patients with RCC during a long follow-up period. 
